The status of real-world treatments for nAMD and DME and what’s coming next - Ophthalmology Times

TL;DR Recent advancements in treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are reshaping patient outcomes. This article addresses current therapies, ongoing clinical trials, and future potential innovations in ophthalmology. Understanding nAMD and DME Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) remain significant challenges in ophthalmology. These conditions can lead to severe vision loss, affecting millions globally. Fortunately, advancements in treatment options are emerging, with ongoing clinical trials promising even more effective solutions. Current Treatment Landscape Currently, anti-VEGF (vascular endothelial growth factor) therapies dominate the treatment landscape for nAMD and DME. Medications like aflibercept and ranibizumab have shown considerable success in stabilizing vision and preventing progression. However, the need for frequent injections poses a challenge for many patients.